Maxime Dely: Helping Patients Live More Freely with Sickle Cell Disease
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Sickle cell disease: an invisible illness with very real consequences
Often invisible from the outside, sickle cell disease remains one of the most common genetic disorders in France, affecting around 30.000 people. Behind this apparent invisibility lies a chronic condition that can deeply impact daily life.
This disease is caused by a genetic abnormality of hemoglobin, leading to the deformation of some red blood cells. Less flexible, these cells struggle to circulate through small blood vessels, causing pain crises, chronic anemia, and sometimes severe organ complications.
Treatment options are diverse: symptomatic care, prevention of complications, transfusions, and today, the development of gene therapies offering real hope for curative treatment.
Among the most effective approaches, red blood exchange by apheresis makes it possible to remove altered red blood cells and replace them with healthy donor red blood cells. This technique reduces blood viscosity, limits iron overload, and helps space out treatment sessions.
Beyond every protocol, there is one simple goal: helping patients live more freely.”
Other posts featuring Maxime Dely on Hemostasis Today.
-
Jul 3, 2026, 18:24Alexandros Rampotas: Targeting Mutant CALR With Precision CAR-T Therapy
-
Jul 3, 2026, 18:08Ram Khandelwal: Why AI Is Transforming Patient Education and the Future of Healthcare
-
Jul 3, 2026, 17:55Miguel Bronchud: Why Congenital Neutropenia Is Often Missed
-
Jul 3, 2026, 17:35Patrick Rensen: Celebrating 25 Years in Endocrinology at Leiden University Medical Center
-
Jul 3, 2026, 16:54Alberico Catapano: The Role of Triglyceride Variability and the AIFA Reimbursement Gap
-
Jul 3, 2026, 16:44Barbara Lovrencic: Amplifying the Patient Voice at the EMA – Shaping the Future of ITP Care
-
Jul 3, 2026, 16:34Andrea Bisso: Exploring the T Cell Engagers in Autoimmune Diseases
-
Jul 3, 2026, 16:24Rizwan Ullah: Managing Severe Tirofiban-Induced Thrombocytopenia
-
Jul 3, 2026, 16:17Neeraj Jain: Maharashtra Strengthens Hemoglobinopathies and Thalassemia Care Through Integrated Public Health Collaboration